查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1809756

全球抗生素抗药性市场（按服务、病原体类型、感染类型和最终用途）预测（2025-2030 年）

Antibiotic Resistance Market by Offering, Pathogen Type, Infection Type, End Use - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2024 年全球抗生素抗药性市场规模为 75.1 亿美元，预计 2025 年将达到 79.6 亿美元，复合年增长率为 6.12%，到 2030 年将达到 107.3 亿美元。

主要市场统计数据
基准年：2024年 75.1亿美元
预计年份：2025年 79.6亿美元
预测年份：2030年 107.3亿美元
复合年增长率（%） 6.12%

了解医疗保健系统中日益严峻的抗生素抗药性挑战以及全球相关人员面临的关键问题

随着抗生素抗药性以前所未有的速度加剧，全球医疗体係正面临严峻危机。曾经易受标准疗法影响的病原体正在进化机制，以逃避我们曾经可靠的药物库。结果，社区面临更长的住院时间、更高的医疗成本和更高的死亡率。在这种情况下，理解科学创新、政策改革和临床实践之间的相互作用至关重要。

绘製抗生素开发平臺、法规结构和全球卫生政策的变革性变化，重塑治疗策略和市场现实

一系列科学突破、监管格局的调整以及资金筹措机制的演变，正在重塑抗生素格局。近年来，自适应试验设计加速了候选药物的筛检，而人工智慧和机器学习平台简化了标靶识别和先导化合物的最佳化。同时，监管机构正在推出奖励，以促进新药开发，强调向基于价值的核准路径和快速审查的模式转移。

评估2025年美国关税政策对抗生素供应链研发投入和市场进入的深远影响

美国于2025年实施的关税措施，为抗生素供应链的平衡引入了一个新变数。透过提高关键中间体、成品製剂和关键原材料的关税，这些政策已波及整个生产流程，导致单位成本上升，利润率受到挤压。成本基数的增加促使采购团队重新协商供应商合同，并探索其他采购方案，从而改变了根深蒂固的供应链关係。

按产品、病原体类型、感染类型和最终用途类别进行市场细分，以确定目标商业机会和策略挑战

稳健的细分框架揭示了不同的策略潜力和抗药性挑战。依应用类型划分，Aminoglycosides对革兰氏阴性菌表现出强效杀菌活性，但由于其治疗指数较窄，需要密切监测。头孢菌素类药物具有广谱抗菌谱，但在医院获得性感染中抗药性较高。同时，儘管有肾毒性的担忧，醣肽仍然是治疗严重革兰氏阳性感染疾病的主要药物。Oxazolidinone、磺胺类药物和四环霉素在作用机转和安全性方面各有特色，需要采取量身订做的管理方法。

确定美洲、欧洲、中东和非洲地区以及亚太地区的市场动态，突显市场驱动因素和挑战

抗生素抗药性的动态和战略重点因地区而异。在美洲，成熟的监管途径和报销框架支持采用先进的治疗创新。然而，频谱药物在门诊病人的广泛使用加速了抗药性表型的出现，导致更严格的管理指南和处方限制。同时，拉丁美洲市场受到供应链不一致和监管实施差异的困扰，导致高风险病原体在区域性疫情爆发。

分析抗生素研发和商业化的大型製药企业和新兴创新者，揭示他们的竞争策略、产品系列和合作网络

一群老牌製药公司凭藉其多元化的产品系列和广泛的全球影响力，持续支撑着抗生素市场。这些行业领导者优先采取平衡的策略，逐步改进现有抗生素类别，并投资于噬菌体疗法和抗菌肽等突破性治疗方法。同时，新兴生技公司则专注于精准标靶机制，利用先进的筛检平台发现不易产生抗药性的新型支架，从而开拓利基市场。

为产业领导者制定可行的策略建议，以加强抗生素管理、推动创新、加强合作并降低抗药性风险

产业领导者必须采取多管齐下的策略策略，有效应对抗生素抗药性情势。首先，加强抗生素管理计画至关重要。这包括将决策支援工具纳入电子健康记录，以指导处方医师选择最佳给药方案和窄频谱药物。其次，企业应加快早期发现平台的投资，优先考虑能够规避现有抗药性机制的新标靶和创新治疗方法。

严谨的调查方法的细节，结合定性专家咨询、定量数据分析和全面的二次研究，以确保分析的稳健性

本报告采用严谨、多层次的调查方法，以确保分析的稳健性和事实的准确性。主要研究包括对30多位製药公司高阶主管、临床微生物学家、政策顾问以及感染疾病控制领域的关键意见领袖的深入访谈。这些访谈揭示了关于策略重点、营运挑战和市场预期的定性背景。

整合对日益增长的市场转型和抗生素抗药性策略路径的关键洞察，为决策者提供清晰的洞察力，以便进行主动规划

抗生素抗药性已超越单纯的临床问题，成为一项决定性的政策、经济和公共卫生挑战。不断变化的情况要求相关人员采取整合策略，将创新研究、灵活的监管参与和强有力的管理结合起来，以保障现有治疗方法的有效性，同时加速新治疗方法的研发。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章市场动态

  • 针对多重抗药性革兰氏阴性病菌感染的新型β-内酰胺酶抑制剂的出现
  • 将快速分子诊断融入医院环境以优化抗生素管理
  • 噬菌体疗法在应对抗生素抗药性病原体方面取得进展
  • 人工智慧驱动的抗生素发现平台的成长将加速先导药物最适化
  • 在中低收入国家扩大全球抗生素管理项目
  • 监管奖励和推拉式资金筹措模式推动抗生素研发创新
  • 开发基于 CRISPR 的抗菌剂，精确靶向病原体
  • 引入微生物调节疗法来预防感染并减少抗生素依赖
  • 生技公司与大型製药公司合作开发新型抗生素，以填补研发管线空白

第六章 市场洞察

  • 波特五力分析
  • PESTEL分析

第七章 2025年美国关税的累积影响

第 8 章抗生素抗药性市场：透过提供

  • 联合治疗
  • 药物
    • Aminoglycosides
    • β-内酰胺类
    • Fluoroquinolones
    • 糖肽
    • 大环内酯类
    • Oxazolidinone
    • 多粘菌素
    • 磺胺类药物
    • 四环霉素
  • 免疫调节药物
  • 单株抗体
  • 噬菌体疗法

9. 抗生素抗药性市场（依病原体类型）

  • 鲍曼不动鲍氏不动桿菌（A. baumannii）
  • 大肠桿菌
  • 肺炎克雷伯菌（K. pneumoniae）
  • 铜绿假单胞菌
  • 金黄色葡萄球菌（S. aureus）
  • 肺炎链球菌

第 10 章抗生素抗药性市场（依感染类型）

  • 急性细菌性皮肤和皮肤结构感染疾病（ABSSSI）
  • 血流感染疾病（BSI）
  • 困难梭状桿菌感染疾病（CDI）
  • 社区型细菌性肺炎（CABP）
  • 复杂性尿道感染（cUTI）

第 11 章抗生素抗药性市场：依最终用途

  • 门诊治疗中心
  • 诊断实验室
  • 医院和诊所
  • 研究所

12. 美洲抗生素抗药性市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

13. 欧洲、中东和非洲的抗生素抗药性市场

  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 阿拉伯聯合大公国
  • 沙乌地阿拉伯
  • 南非
  • 丹麦
  • 荷兰
  • 卡达
  • 芬兰
  • 瑞典
  • 奈及利亚
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波兰
  • 瑞士

14. 亚太地区抗生素抗药性市场

  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
  • 印尼
  • 泰国
  • 菲律宾
  • 马来西亚
  • 新加坡
  • 越南
  • 台湾

第十五章竞争格局

  • 市占率分析（2024年）
  • FPNV定位矩阵（2024年）
  • 竞争分析
    • Abbott Laboratories
    • AbbVie Inc.
    • Basilea Pharmaceutica Ltd
    • bioMerieux SA
    • Cipla Limited
    • Cumberland Pharmaceuticals
    • F. Hoffmann-La Roche Ltd
    • GlaxoSmithKline plc
    • Innoviva, Inc.
    • Johnson & Johnson Services, Inc.
    • Novo Holdings A/S
    • Pfizer Inc.
    • Sandoz AG
    • Shionogi & Co., Ltd.
    • Teva Pharmaceutical Industries Ltd.

第十六章 研究人工智慧

第十七章 研究统计

第十八章 研究联络人

第十九章 研究报导

第二十章 附录

Product Code: MRR-535C629188E6

The Antibiotic Resistance Market was valued at USD 7.51 billion in 2024 and is projected to grow to USD 7.96 billion in 2025, with a CAGR of 6.12%, reaching USD 10.73 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 7.51 billion
Estimated Year [2025] USD 7.96 billion
Forecast Year [2030] USD 10.73 billion
CAGR (%) 6.12%

Unveiling the Escalating Challenge of Antibiotic Resistance Across Healthcare Systems and the Critical Imperatives for Stakeholders Worldwide

Healthcare systems around the globe are confronting a mounting crisis as antibiotic resistance accelerates at an unprecedented pace. Pathogens that were once susceptible to standard treatments are evolving mechanisms to evade the once-reliable weapons in our pharmaceutical arsenal. As a result, communities face longer hospital stays, higher medical costs, and a growing mortality burden. In this context, understanding the interplay of scientific innovation, policy reform, and clinical practice has become critical.

Stakeholders across the continuum-from policy-makers to hospital administrators, from research institutions to pharmaceutical executives-must navigate this volatile environment. They require not only real-time visibility into emerging resistance patterns but also a holistic strategy that aligns discovery pipelines with stewardship initiatives. This introductory section lays the groundwork by framing antibiotic resistance as both a public health emergency and a catalyst for transformative industry responses.

Mapping the Transformative Shifts in Antibiotic Development Pipelines Regulatory Frameworks and Global Health Policies Reshaping Therapeutic Strategies and Market Realities

The antibiotic landscape is being reshaped by a confluence of scientific breakthroughs, regulatory recalibrations, and evolving funding mechanisms. In recent years, adaptive trial designs have accelerated candidate screening, while artificial intelligence and machine learning platforms have streamlined target identification and lead optimization. Simultaneously, regulatory bodies have introduced incentives to stimulate development of novel agents, underscoring a paradigm shift toward value-based approval pathways and expedited reviews.

Moreover, collaborations between public institutions, non-profit consortia, and private enterprises are forging new models for risk sharing and resource pooling. These partnerships are fundamental to overcoming the traditional barriers of cost and complexity, especially in late-stage clinical trials where financial exposure can be prohibitive. Accordingly, we are witnessing a strategic realignment in which stakeholder networks are moving beyond transactional alliances to enduring consortiums, thereby distributing both risk and reward more equitably across the antibiotic innovation ecosystem.

At the same time, global health policies are adjusting to the reality that stewardship and access must be balanced. Initiatives aimed at curbing overuse are now being integrated with mechanisms to ensure equitable distribution, particularly in low- and middle-income nations. The result is a more nuanced regulatory environment that demands adaptive commercial strategies and informed advocacy efforts to synchronize market entry with public health objectives.

Assessing the Far-Reaching Consequences of United States Tariff Policies on Antibiotic Supply Chains R&D Investments and Market Accessibility in 2025

United States tariff measures introduced in 2025 have introduced a new variable into the antibiotic supply chain equation. By raising duties on critical intermediates, finished dosage forms, and key raw materials, these policies have cascaded through manufacturing workflows, elevating unit costs and exerting pressure on profit margins. The increased cost base has spurred procurement teams to renegotiate supplier contracts and explore alternative sourcing arrangements, thereby altering entrenched supply-chain relationships.

In parallel, the tariff landscape has prompted multinational companies to reassess their production footprints. Some organizations have initiated feasibility studies to relocate manufacturing closer to end markets or to establish dual-sourcing agreements to mitigate exposure. Consequently, lead times have lengthened for certain molecule classes, introducing variability in inventory cycles and compelling downstream stakeholders to build additional stock buffers to safeguard against potential disruptions.

Perhaps most impactful is the ripple effect on research and development budgets. As companies absorb tariff-related cost increases, discretionary funding for early-stage research faces tighter scrutiny. Projects targeting high-risk pathogen classes may experience reprioritization, while investment committees demand clearer return-on-investment thresholds. This environment compels a recalibration of portfolio strategies, emphasizing asset triage and the pursuit of collaborative funding mechanisms to share developmental costs and expedite time-to-proof of concept.

Deconstructing Market Segmentation Across Drug Classes Pathogen Types Infection Variants and End Use Categories to Illuminate Targeted Opportunities and Strategic Imperatives

A robust segmentation framework illuminates distinct pockets of strategic potential and resistance challenges. Across drug classes, Aminoglycosides exhibit potent bactericidal action against Gram-negative organisms but carry a narrow therapeutic index that necessitates vigilant monitoring. Cephalosporins offer broad-spectrum coverage yet have encountered elevated resistance rates in hospital-acquired infections. Combination Therapies are increasingly favored for their synergistic efficacy against multidrug-resistant strains, while Glycopeptides remain a mainstay for severe Gram-positive infections despite concerns of nephrotoxicity. Oxazolidinones, Sulfonamides, and Tetracyclines each present unique profiles in terms of mechanism of action and safety considerations, prompting tailored stewardship approaches.

On the pathogen front, Acinetobacter baumannii has emerged as a formidable adversary in critical care settings, leveraging adaptive efflux pumps and biofilm formation to thwart intervention. Escherichia coli continues to drive community and hospital onset urinary tract infections, with plasmid-mediated resistance genes proliferating across geographic regions. Klebsiella pneumoniae maintains a high prevalence in ventilator-associated pneumonia, often harboring carbapenemase enzymes that render last-resort treatments ineffective. Pseudomonas aeruginosa's intrinsic resistance coupled with its ability to acquire novel determinants has cemented its status as a priority pathogen. Meanwhile, Staphylococcus aureus and Streptococcus pneumoniae persist as leading causes of both invasive and non-invasive infections, despite decades of targeted vaccine and antibiotic development.

Infection type segmentation reveals that Acute Bacterial Skin & Skin Structure Infections pose a persistent challenge in outpatient and surgical wound contexts, while Bloodstream Infections demand urgent, broad-spectrum coverage to prevent systemic spread. Clostridioides difficile Infection has surged in frequency and severity, prompting focus on narrow-spectrum therapies and microbiome-based interventions. Community-Acquired Bacterial Pneumonia remains a critical driver of hospital admissions, particularly among vulnerable elderly populations, and Complicated Urinary Tract Infections underscore the need for agents with both potent activity and favorable safety profiles.

End-use categories further refine strategic focus. Ambulatory Care Centers are driving demand for oral formulations and outpatient infusion services. Diagnostic Laboratories play an increasingly central role in rapid pathogen identification and susceptibility profiling, accelerating the shift from empirical to precision prescribing. Hospitals & Clinics continue to dominate acute-care utilization, necessitating robust formulary strategies and integrated stewardship protocols. Research Institutes serve as incubators for next-generation modalities, advancing preclinical platforms that may redefine the future of antibiotic discovery.

Delineating Regional Market Dynamics Across the Americas Europe Middle East Africa and Asia Pacific to Highlight Growth Drivers and Emerging Challenges

Regional heterogeneity continues to shape antibiotic resistance dynamics and strategic priorities. In the Americas, well-established regulatory pathways and reimbursement frameworks support the adoption of advanced therapeutic innovations. However, the pervasive use of broad-spectrum agents in outpatient settings has accelerated the emergence of resistant phenotypes, leading to more stringent stewardship guidelines and formulary restrictions. Meanwhile, Latin American markets are grappling with inconsistent supply chains and variable regulatory enforcement, contributing to localized outbreaks of high-risk pathogens.

Across Europe, Middle East & Africa, fragmented healthcare infrastructures and varying levels of access to diagnostic technology complicate coordinated stewardship efforts. In Western Europe, centralized procurement and pan-regional surveillance networks have enabled more cohesive responses to resistance trends. By contrast, emerging markets in the Middle East and Africa face challenges in laboratory capacity, cold-chain logistics, and regulatory alignment, driving reliance on off-patent generics and impeding uptake of novel agents.

Asia-Pacific presents a dual narrative of rapid innovation and persistent public health hurdles. Markets such as Japan, Australia, and South Korea boast sophisticated R&D ecosystems and proactive policy frameworks. At the same time, densely populated regions in Southeast Asia and South Asia experience high rates of antibiotic consumption, often driven by over-the-counter availability and under-resourced stewardship programs. This juxtaposition underscores both the promise of regional leadership in next-generation therapies and the imperative for coordinated cross-border initiatives to curb resistance transmission.

Analyzing Leading Pharmaceutical Players and Emerging Innovators Across Antibiotic R&D and Commercialization to Uncover Competitive Strategies Product Portfolios and Collaborative Networks

A cadre of established pharmaceutical companies continues to anchor the antibiotic market through diversified product portfolios and expansive global reach. These industry leaders prioritize a balanced approach between incremental improvements to existing classes and investments in breakthrough modalities, such as bacteriophage therapies and antimicrobial peptides. Meanwhile, emerging biotechs are carving out niche positions by focusing on precision-targeted mechanisms, leveraging advanced screening platforms to unearth novel scaffolds with reduced propensity for resistance development.

Strategic alliances have become a hallmark of the competitive landscape. Cross-sector partnerships between pharma giants and biotech innovators facilitate agile progression of assets through preclinical validation into early clinical trials. At the same time, consortium models-often supported by government grants and non-profit funding-are aggregating pooled resources to de-risk the development of ultra-narrow-spectrum candidates against priority pathogens.

In the commercialization phase, companies are adopting dynamic pricing and value-based contracting arrangements, linking reimbursement to real-world outcomes data. Such initiatives reflect a growing emphasis on aligning stakeholder incentives to reward both clinical efficacy and responsible utilization. As a result, entities that can demonstrate robust pharmacovigilance mechanisms and post-market surveillance capabilities are gaining a competitive edge, reinforcing the notion that superior product performance extends beyond the laboratory bench.

Formulating Actionable Strategic Recommendations for Industry Leaders to Enhance Antibiotic Stewardship Drive Innovation Strengthen Collaborations and Mitigate Resistance Risks

Industry leaders must adopt a multifaceted strategic playbook to navigate the antibiotic resistance landscape effectively. First, strengthening antimicrobial stewardship programs is paramount; this includes embedding decision-support tools within electronic health records to guide prescribers toward optimal dosing regimens and narrow-spectrum selections. Second, firms should accelerate investment in early-stage discovery platforms, prioritizing novel targets and innovative modalities that circumvent existing resistance mechanisms.

Simultaneously, fostering cross-sector collaboration will amplify impact. Pharmaceutical companies, academic institutions, and non-profit foundations should co-create funding consortia aimed at de-risking high-value projects. By sharing precompetitive data and co-developing clinical trial networks, these alliances can streamline development timelines and distribute financial exposure.

Engagement with regulatory bodies is equally critical. Companies must proactively shape policy dialogues on breakthrough therapy designations, adaptive licensing frameworks, and reimbursement models tied to long-term efficacy data. Clear, evidence-driven advocacy can help align public health objectives with commercial incentives, ensuring that novel agents reach patients without undue delay.

Finally, leveraging real-world evidence and digital health solutions will differentiate market leaders. Telemedicine platforms, rapid diagnostic integration, and post-market surveillance apps can provide granular usage and outcome data. By harnessing these insights, organizations can refine clinical guidelines, demonstrate value to payers, and reinforce responsible prescribing practices across care settings.

Detailing the Rigorous Research Methodology Combining Qualitative Expert Consultations Quantitative Data Analysis and Comprehensive Secondary Research to Ensure Analytical Robustness

This report is underpinned by a rigorous, multi-layered research methodology designed to ensure analytical robustness and factual precision. Primary research comprised in-depth interviews with over 30 senior executives across pharmaceutical companies, clinical microbiologists, policy advisors, and key opinion leaders in infectious disease management. These conversations provided qualitative context around strategic priorities, operational challenges, and market expectations.

Quantitative data collection drew on a wide array of reputable sources, including peer-reviewed journals, regulatory agency publications, hospital procurement records, and patient outcome registries. Data points were meticulously validated through cross-referencing and triangulation to safeguard against bias or inconsistency. In addition, supply chain analytics were integrated to model cost impacts, inventory flows, and lead-time variability under different tariff scenarios.

Secondary research efforts encompassed a comprehensive review of treatment guidelines, policy whitepapers, and global surveillance reports. Special attention was given to emerging regulatory directives and stewardship frameworks, enabling a nuanced understanding of how shifting policies influence both clinical practice and commercial strategy.

Finally, all insights underwent rigorous peer review by an internal panel of domain experts to confirm accuracy, relevance, and forward-looking applicability. This layered approach ensures that conclusions and recommendations are grounded in both empirical evidence and strategic foresight.

Synthesizing Critical Findings on Antibiotic Resistance Escalation Market Transformations and Strategic Pathways to Equip Decision Makers with Clear Insight for Proactive Planning

Antibiotic resistance has transcended a purely clinical concern to become a defining challenge that intersects policy, economics, and public health. The evolving landscape demands that stakeholders adopt integrated strategies, combining innovative research, agile regulatory engagement, and robust stewardship to safeguard the efficacy of existing therapies while accelerating the advent of new ones.

Strategic segmentation by drug class, pathogen type, infection variant, and end use has revealed differentiated areas of focus, guiding targeted investment and commercialization plans. Meanwhile, regional dynamics underscore the need for tailored approaches that reflect local infrastructure, regulatory environments, and cultural prescribing habits. In this complex ecosystem, leading companies are leveraging partnerships, adaptive trial designs, and digital tools to maintain competitive momentum. Looking ahead, the most successful entities will be those that align stakeholder incentives, embrace data-driven decision making, and foster collaborative networks across the public and private sectors.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Emergence of novel beta-lactamase inhibitors targeting multidrug-resistant gram-negative infections
  • 5.2. Integration of rapid molecular diagnostics in hospital settings to optimize antibiotic stewardship
  • 5.3. Advancements in bacteriophage therapy pipelines addressing antibiotic recalcitrant pathogens
  • 5.4. Growth of AI-driven antibiotic discovery platforms for accelerated lead optimization
  • 5.5. Expansion of global antimicrobial stewardship programs in low and middle income countries
  • 5.6. Regulatory incentives and push-pull funding models driving innovation across antibiotic R&D
  • 5.7. Development of CRISPR-based antimicrobial agents for precise pathogen targeting
  • 5.8. Adoption of microbiome modulation therapies to prevent infection and reduce antibiotic reliance
  • 5.9. Biotech and big pharma collaborations focusing on novel antibiotic classes to fill pipeline gaps

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Antibiotic Resistance Market, by Offering

  • 8.1. Introduction
  • 8.2. Combination Therapies
  • 8.3. Drugs
    • 8.3.1. Aminoglycosides
    • 8.3.2. Beta-Lactams
    • 8.3.3. Fluoroquinolones
    • 8.3.4. Glycopeptides
    • 8.3.5. Macrolides
    • 8.3.6. Oxazolidinones
    • 8.3.7. Polymyxins
    • 8.3.8. Sulfonamides
    • 8.3.9. Tetracyclines
  • 8.4. Immunomodulators
  • 8.5. Monoclonal Antibodies
  • 8.6. Phage Therapy

9. Antibiotic Resistance Market, by Pathogen Type

  • 9.1. Introduction
  • 9.2. Acinetobacter Paumannii (A. baumannii)
  • 9.3. Escherichia Coli (E. coli)
  • 9.4. Klebsiella Pneumoniae (K. pneumoniae)
  • 9.5. Pseudomonas Aeruginosa (P. aeruginosa)
  • 9.6. Staphylococcus Aureus (S. aureus)
  • 9.7. Streptococcus Pneumonia (S. pneumoniae)

10. Antibiotic Resistance Market, by Infection Type

  • 10.1. Introduction
  • 10.2. Acute Bacterial Skin & Skin Structure Infections (ABSSSI)
  • 10.3. Bloodstream Infections (BSI)
  • 10.4. Clostridioides difficile Infection (CDI)
  • 10.5. Community-Acquired Bacterial Pneumonia (CABP)
  • 10.6. Complicated Urinary Tract Infections (cUTI)

11. Antibiotic Resistance Market, by End Use

  • 11.1. Introduction
  • 11.2. Ambulatory Care Centers
  • 11.3. Diagnostic Laboratories
  • 11.4. Hospitals & Clinics
  • 11.5. Research Institutes

12. Americas Antibiotic Resistance Market

  • 12.1. Introduction
  • 12.2. United States
  • 12.3. Canada
  • 12.4. Mexico
  • 12.5. Brazil
  • 12.6. Argentina

13. Europe, Middle East & Africa Antibiotic Resistance Market

  • 13.1. Introduction
  • 13.2. United Kingdom
  • 13.3. Germany
  • 13.4. France
  • 13.5. Russia
  • 13.6. Italy
  • 13.7. Spain
  • 13.8. United Arab Emirates
  • 13.9. Saudi Arabia
  • 13.10. South Africa
  • 13.11. Denmark
  • 13.12. Netherlands
  • 13.13. Qatar
  • 13.14. Finland
  • 13.15. Sweden
  • 13.16. Nigeria
  • 13.17. Egypt
  • 13.18. Turkey
  • 13.19. Israel
  • 13.20. Norway
  • 13.21. Poland
  • 13.22. Switzerland

14. Asia-Pacific Antibiotic Resistance Market

  • 14.1. Introduction
  • 14.2. China
  • 14.3. India
  • 14.4. Japan
  • 14.5. Australia
  • 14.6. South Korea
  • 14.7. Indonesia
  • 14.8. Thailand
  • 14.9. Philippines
  • 14.10. Malaysia
  • 14.11. Singapore
  • 14.12. Vietnam
  • 14.13. Taiwan

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Abbott Laboratories
    • 15.3.2. AbbVie Inc.
    • 15.3.3. Basilea Pharmaceutica Ltd
    • 15.3.4. bioMerieux S.A.
    • 15.3.5. Cipla Limited
    • 15.3.6. Cumberland Pharmaceuticals
    • 15.3.7. F. Hoffmann-La Roche Ltd
    • 15.3.8. GlaxoSmithKline plc
    • 15.3.9. Innoviva, Inc.
    • 15.3.10. Johnson & Johnson Services, Inc.
    • 15.3.11. Novo Holdings A/S
    • 15.3.12. Pfizer Inc.
    • 15.3.13. Sandoz AG
    • 15.3.14. Shionogi & Co., Ltd.
    • 15.3.15. Teva Pharmaceutical Industries Ltd.

16. ResearchAI

17. ResearchStatistics

18. ResearchContacts

19. ResearchArticles

20. Appendix

LIST OF FIGURES

  • FIGURE 1. ANTIBIOTIC RESISTANCE MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 14. AMERICAS ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 16. UNITED STATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. ANTIBIOTIC RESISTANCE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 22. ANTIBIOTIC RESISTANCE MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 23. ANTIBIOTIC RESISTANCE MARKET: RESEARCHAI
  • FIGURE 24. ANTIBIOTIC RESISTANCE MARKET: RESEARCHSTATISTICS
  • FIGURE 25. ANTIBIOTIC RESISTANCE MARKET: RESEARCHCONTACTS
  • FIGURE 26. ANTIBIOTIC RESISTANCE MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. ANTIBIOTIC RESISTANCE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY AMINOGLYCOSIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY AMINOGLYCOSIDES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY BETA-LACTAMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY BETA-LACTAMS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY FLUOROQUINOLONES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY FLUOROQUINOLONES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY GLYCOPEPTIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY GLYCOPEPTIDES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY MACROLIDES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY OXAZOLIDINONES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY OXAZOLIDINONES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY POLYMYXINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY POLYMYXINS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY SULFONAMIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY SULFONAMIDES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY TETRACYCLINES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY PHAGE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY PHAGE THERAPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY ACINETOBACTER PAUMANNII (A. BAUMANNII), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY ACINETOBACTER PAUMANNII (A. BAUMANNII), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY ESCHERICHIA COLI (E. COLI), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY ESCHERICHIA COLI (E. COLI), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY KLEBSIELLA PNEUMONIAE (K. PNEUMONIAE), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY KLEBSIELLA PNEUMONIAE (K. PNEUMONIAE), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY PSEUDOMONAS AERUGINOSA (P. AERUGINOSA), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY PSEUDOMONAS AERUGINOSA (P. AERUGINOSA), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY STAPHYLOCOCCUS AUREUS (S. AUREUS), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY STAPHYLOCOCCUS AUREUS (S. AUREUS), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY STREPTOCOCCUS PNEUMONIA (S. PNEUMONIAE), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY STREPTOCOCCUS PNEUMONIA (S. PNEUMONIAE), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTIONS (ABSSSI), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTIONS (ABSSSI), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY BLOODSTREAM INFECTIONS (BSI), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY BLOODSTREAM INFECTIONS (BSI), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY CLOSTRIDIOIDES DIFFICILE INFECTION (CDI), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY CLOSTRIDIOIDES DIFFICILE INFECTION (CDI), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA (CABP), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA (CABP), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 65. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY COMPLICATED URINARY TRACT INFECTIONS (CUTI), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY COMPLICATED URINARY TRACT INFECTIONS (CUTI), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 67. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 69. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 71. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 73. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 75. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 77. AMERICAS ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 78. AMERICAS ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2025-2030 (USD MILLION)
  • TABLE 79. AMERICAS ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 80. AMERICAS ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2025-2030 (USD MILLION)
  • TABLE 81. AMERICAS ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 82. AMERICAS ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 83. AMERICAS ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 84. AMERICAS ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2025-2030 (USD MILLION)
  • TABLE 85. AMERICAS ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 86. AMERICAS ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 87. AMERICAS ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. AMERICAS ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 89. UNITED STATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 90. UNITED STATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2025-2030 (USD MILLION)
  • TABLE 91. UNITED STATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 92. UNITED STATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2025-2030 (USD MILLION)
  • TABLE 93. UNITED STATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 94. UNITED STATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 95. UNITED STATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 96. UNITED STATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2025-2030 (USD MILLION)
  • TABLE 97. UNITED STATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 98. UNITED STATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 99. UNITED STATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 100. UNITED STATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 101. CANADA ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 102. CANADA ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2025-2030 (USD MILLION)
  • TABLE 103. CANADA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 104. CANADA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2025-2030 (USD MILLION)
  • TABLE 105. CANADA ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 106. CANADA ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 107. CANADA ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 108. CANADA ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2025-2030 (USD MILLION)
  • TABLE 109. CANADA ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 110. CANADA ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 111. MEXICO ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 112. MEXICO ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2025-2030 (USD MILLION)
  • TABLE 113. MEXICO ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 114. MEXICO ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2025-2030 (USD MILLION)
  • TABLE 115. MEXICO ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 116. MEXICO ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 117. MEXICO ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 118. MEXICO ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2025-2030 (USD MILLION)
  • TABLE 119. MEXICO ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 120. MEXICO ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 121. BRAZIL ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 122. BRAZIL ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2025-2030 (USD MILLION)
  • TABLE 123. BRAZIL ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 124. BRAZIL ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2025-2030 (USD MILLION)
  • TABLE 125. BRAZIL ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 126. BRAZIL ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 127. BRAZIL ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 128. BRAZIL ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2025-2030 (USD MILLION)
  • TABLE 129. BRAZIL ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 130. BRAZIL ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 131. ARGENTINA ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 132. ARGENTINA ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2025-2030 (USD MILLION)
  • TABLE 133. ARGENTINA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 134. ARGENTINA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2025-2030 (USD MILLION)
  • TABLE 135. ARGENTINA ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 136. ARGENTINA ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 137. ARGENTINA ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 138. ARGENTINA ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2025-2030 (USD MILLION)
  • TABLE 139. ARGENTINA ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 140. ARGENTINA ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2025-2030 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2025-2030 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2025-2030 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 153. UNITED KINGDOM ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 154. UNITED KINGDOM ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2025-2030 (USD MILLION)
  • TABLE 155. UNITED KINGDOM ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 156. UNITED KINGDOM ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2025-2030 (USD MILLION)
  • TABLE 157. UNITED KINGDOM ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 158. UNITED KINGDOM ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 159. UNITED KINGDOM ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 160. UNITED KINGDOM ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2025-2030 (USD MILLION)
  • TABLE 161. UNITED KINGDOM ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 162. UNITED KINGDOM ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 163. GERMANY ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 164. GERMANY ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2025-2030 (USD MILLION)
  • TABLE 165. GERMANY ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 166. GERMANY ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2025-2030 (USD MILLION)
  • TABLE 167. GERMANY ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 168. GERMANY ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 169. GERMANY ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 170. GERMANY ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2025-2030 (USD MILLION)
  • TABLE 171. GERMANY ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 172. GERMANY ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 173. FRANCE ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 174. FRANCE ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2025-2030 (USD MILLION)
  • TABLE 175. FRANCE ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 176. FRANCE ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2025-2030 (USD MILLION)
  • TABLE 177. FRANCE ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 178. FRANCE ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 179. FRANCE ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 180. FRANCE ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2025-2030 (USD MILLION)
  • TABLE 181. FRANCE ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 182. FRANCE ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 183. RUSSIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 184. RUSSIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2025-2030 (USD MILLION)
  • TABLE 185. RUSSIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 186. RUSSIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2025-2030 (USD MILLION)
  • TABLE 187. RUSSIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 188. RUSSIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 189. RUSSIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. RUSSIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2025-2030 (USD MILLION)
  • TABLE 191. RUSSIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 192. RUSSIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 193. ITALY ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 194. ITALY ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2025-2030 (USD MILLION)
  • TABLE 195. ITALY ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 196. ITALY ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2025-2030 (USD MILLION)
  • TABLE 197. ITALY ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 198. ITALY ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 199. ITALY ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. ITALY ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2025-2030 (USD MILLION)
  • TABLE 201. ITALY ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 202. ITALY ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 203. SPAIN ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 204. SPAIN ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2025-2030 (USD MILLION)
  • TABLE 205. SPAIN ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 206. SPAIN ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2025-2030 (USD MILLION)
  • TABLE 207. SPAIN ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. SPAIN ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 209. SPAIN ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 210. SPAIN ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2025-2030 (USD MILLION)
  • TABLE 211. SPAIN ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 212. SPAIN ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 213. UNITED ARAB EMIRATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 214. UNITED ARAB EMIRATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2025-2030 (USD MILLION)
  • TABLE 215. UNITED ARAB EMIRATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 216. UNITED ARAB EMIRATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2025-2030 (USD MILLION)
  • TABLE 217. UNITED ARAB EMIRATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. UNITED ARAB EMIRATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 219. UNITED ARAB EMIRATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. UNITED ARAB EMIRATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2025-2030 (USD MILLION)
  • TABLE 221. UNITED ARAB EMIRATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 222. UNITED ARAB EMIRATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 223. SAUDI ARABIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 224. SAUDI ARABIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2025-2030 (USD MILLION)
  • TABLE 225. SAUDI ARABIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 226. SAUDI ARABIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2025-2030 (USD MILLION)
  • TABLE 227. SAUDI ARABIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 228. SAUDI ARABIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 229. SAUDI ARABIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. SAUDI ARABIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2025-2030 (USD MILLION)
  • TABLE 231. SAUDI ARABIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 232. SAUDI ARABIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 233. SOUTH AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 234. SOUTH AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2025-2030 (USD MILLION)
  • TABLE 235. SOUTH AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 236. SOUTH AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2025-2030 (USD MILLION)
  • TABLE 237. SOUTH AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. SOUTH AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 239. SOUTH AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 240. SOUTH AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2025-2030 (USD MILLION)
  • TABLE 241. SOUTH AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 242. SOUTH AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 243. DENMARK ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 244. DENMARK ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2025-2030 (USD MILLION)
  • TABLE 245. DENMARK ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 246. DENMARK ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2025-2030 (USD MILLION)
  • TABLE 247. DENMARK ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. DENMARK ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 249. DENMARK ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. DENMARK ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2025-2030 (USD MILLION)
  • TABLE 251. DENMARK ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 252. DENMARK ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 253. NETHERLANDS ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 254. NETHERLANDS ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2025-2030 (USD MILLION)
  • TABLE 255. NETHERLANDS ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 256. NETHERLANDS ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2025-2030 (USD MILLION)
  • TABLE 257. NETHERLANDS ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. NETHERLANDS ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 259. NETHERLANDS ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. NETHERLANDS ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2025-2030 (USD MILLION)
  • TABLE 261. NETHERLANDS ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 262. NETHERLANDS ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 263. QATAR ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 264. QATAR ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2025-2030 (USD MILLION)
  • TABLE 265. QATAR ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 266. QATAR ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2025-2030 (USD MILLION)
  • TABLE 267. QATAR ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. QATAR ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 269. QATAR ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 270. QATAR ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2025-2030 (USD MILLION)
  • TABLE 271. QATAR ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 272. QATAR ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 273. FINLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 274. FINLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2025-2030 (USD MILLION)
  • TABLE 275. FINLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 276. FINLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2025-2030 (USD MILLION)
  • TABLE 277. FINLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. FINLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 279. FINLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. FINLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2025-2030 (USD MILLION)
  • TABLE 281. FINLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 282. FINLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 283. SWEDEN ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 284. SWEDEN ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2025-2030 (USD MILLION)
  • TABLE 285. SWEDEN ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 286. SWEDEN ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2025-2030 (USD MILLION)
  • TABLE 287. SWEDEN ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 288. SWEDEN ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 289. SWEDEN ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. SWEDEN ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2025-2030 (USD MILLION)
  • TABLE 291. SWEDEN ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 292. SWEDEN ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 293. NIGERIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 294. NIGERIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2025-2030 (USD MILLION)
  • TABLE 295. NIGERIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 296. NIGERIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2025-2030 (USD MILLION)
  • TABLE 297. NIGERIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. NIGERIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 299. NIGERIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 300. NIGERIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2025-2030 (USD MILLION)
  • TABLE 301. NIGERIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 302. NIGERIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 303. EGYPT ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 304. EGYPT ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2025-2030 (USD MILLION)
  • TABLE 305. EGYPT ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 306. EGYPT ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2025-2030 (USD MILLION)
  • TABLE 307. EGYPT ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 308. EGYPT ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 309. EGYPT ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 310. EGYPT ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2025-2030 (USD MILLION)
  • TABLE 311. EGYPT ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 312. EGYPT ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 313. TURKEY ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 314. TURKEY ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2025-2030 (USD MILLION)
  • TABLE 315. TURKEY ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 316. TURKEY ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2025-2030 (USD MILLION)
  • TABLE 317. TURKEY ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 318. TURKEY ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 319. TURKEY ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 320. TURKEY ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2025-2030 (USD MILLION)
  • TABLE 321. TURKEY ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 322. TURKEY ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 323. ISRAEL ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 324. ISRAEL ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2025-2030 (USD MILLION)
  • TABLE 325. ISRAEL ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 326. ISRAEL ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2025-2030 (USD MILLION)
  • TABLE 327. ISRAEL ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 328. ISRAEL ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 329. ISRAEL ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 330. ISRAEL ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2025-2030 (USD MILLION)
  • TABLE 331. ISRAEL ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 332. ISRAEL ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 333. NORWAY ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 334. NORWAY ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2025-2030 (USD MILLION)
  • TABLE 335. NORWAY ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 336. NORWAY ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2025-2030 (USD MILLION)
  • TABLE 337. N